While the American car market was booming in the '50s, independent carmakers were struggling in the face of the financial ...
Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...
New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...
We’ve launched a first-of-its-kind app to help you find out where your generic drugs come from and see the track records of ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...
Julia is the associate news editor for Health, where she edits and publishes news articles on trending health and wellness topics. Her work has been featured in The Heights, an independent student ...
Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. Natalya Yashina is a CPA, DASM with over 12 years of experience in ...
MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...
Endries International, Brillion, WI, a distributor of fasteners and related production components, has announced that MSD Partners, L.P., along with Endries management, has acquired Endries from ...
Amazon has been the elephant in the wholesale distribution room ever since the eCommerce behemoth began expanding beyond selling books and music CDs in the late 1990s, and especially ever since ...
We publish independently audited content meeting strict editorial standards. Ads on our site are served by Google AdSense and are not controlled or influenced by our editorial team. Discover the ...